News

Medigene participates at three national and international conferences

Martinsried/Munich, 21 April 2016. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at five upcoming national and international conferences:

  • German Biotechnology Days (Deutsche Biotechnologietage)

Date: 26 - 27 April 2016
Location: Leipzig, Germany
Dr. Kai Pinkernell, SVP/Chief Medical Officer (CMO) of Medigene will talk about "Living cancer therapeutics: Highly specific anti-tumour T cells through genetic modification of T-cell receptors", on 27 April during the symposium "The immune system - point of attack" from 2:00 pm - 3:30 pm.

  • 14. Cancer Immunotherapy (CIMT) conference

Date: 10 - 12 May 2016
Location: Mainz, Germany
Members of Prof. Gunnar Kvalheim's academic research group at the Oslo University Hospital will show data on specific immune responses of different AML patients treated with DC vaccines.

  • ASCO Annual Meeting 

Date: 3 - 7 June 2016
Location: Chicago, USA

  • BIO International Convention

Date: 6 - 9 June 2016
Location: San Francisco, USA

  • 9th DVFA Life Science Conference

Date: 14 June 2016
Location: Frankfurt, Germany
Dr. Olav Zilian, SVP Corporate Development of Medigene will give a talk on the topic "Dendritic Vaccines and T-Cell Therapy" from 3:00 pm - 3.30 pm.

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development.  Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.